Highly Profitable Orphans Can Have Exclusivity Reduced Under EC Proposal
Orphan drugs marketed in the European Union that are found to be making an "unreasonable profit" may face a reduction of market exclusivity time, according to the European Commission's proposal for an orphan products regulation.
You may also be interested in...
The European Medicines Evaluation Agency should consider the adoption of more FDA-style mechanisms to speed approval of important new drugs, Commission for Proprietary Medicinal Products Chairman Jean-Michel Alexandre, PhD, indicated.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011